- Home
- VRCA vs GNTA Comparison
VRCA vs GNTA Comparison
Compare VRCA & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | GNTA |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 39.4M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VRCA | GNTA |
|---|---|---|
| Price | $8.90 | $1.89 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 368.2K | 122.5K |
| Earning Date | 11-14-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,829,000.00 | N/A |
| Revenue This Year | $332.45 | N/A |
| Revenue Next Year | $12.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 234.73 | N/A |
| 52 Week Low | $3.28 | $1.35 |
| 52 Week High | $12.00 | $10.00 |
Technical Indicators
Market Signals| Indicator | VRCA | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 71.77 | 40.49 |
| Support Level | $6.26 | $1.80 |
| Resistance Level | $9.82 | $2.20 |
| Average True Range (ATR) | 1.02 | 0.24 |
| MACD | 0.42 | 0.04 |
| Stochastic Oscillator | 83.64 | 59.77 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.